Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors

Armen Yuri Gasparyan; George D. Kitas

Language:

Volume 35, Issue 1, March 2024

Back to the list

Mediterr J Rheumatol 2022;33(2):173-5

Article Links

Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors

Armen Yuri Gasparyan¹, George D. Kitas^1,2

Authors Information

¹Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, United Kingdom

²Centre for Epidemiology versus Arthritis, University of Manchester, Manchester, United Kingdom

AY Gasparyan, GD Kitas

Abstract

This paper has no abstract.

Cite this article as: Gasparyan AY, Kitas GD. Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors. Mediterr J Rheumatol 2022;33(2):173-5

Article Submitted: 15 Jun 2022; Article Accepted: 16 Jun 2022; Available Online: 30 Jun 2022

https://doi.org/10.31138/mjr.33.2.173

This work is licensed under a Creative Commons Attribution 4.0 International License.

Keywords: anakinra, canakinumab, COVID-19, cytokine release syndrome, hereditary autoinflammatory diseases, interleukin-1, interleukin-6